Teva Announces Launch of a Generic Version of NuvaRing® (etonogestrel and ethinyl estradiol) Vaginal Ring in the United States
TEL AVIV, Israel & PARSIPPANY, N.J.: Teva Pharmaceuticals USA, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd., has announced the availability of a generic version of NuvaRing®1 (etonogestrel and ethinyl estradiol vaginal ring), 0.120 mg/0.015 mg per day, in the U.S. Teva’s AB-rated and bioequivalent etonogestrel and ethinyl estradiol vaginal ring, is an estrogen/progestin combination hormonal contraceptive (CHC) indicated for use by women to prevent pregnancy.
“The launch of a generic version of NuvaRing Vaginal Ring in the U.S. is an important addition to Teva’s generic portfolio,” said Christine Baeder, SVP, Chief Operating Officer US Generics, Teva USA. “With more than 40 generic products in our existing woman’s health portfolio, we are proud to add another accessible contraception option.”
With nearly 550 generic medicines available, Teva has the largest portfolio of FDA-approved generic products on the market and holds the leading position in first-to-file opportunities, with over 100 pending first-to-files in the U.S. Currently, one in ten generic prescriptions dispensed in the U.S. is filled with a Teva generic product.
Etonogestrel and ethinyl estradiol vaginal ring products have annual sales of more than $837 million in the U.S., according to IQVIA data as of November 2020.
